Dogwood Therapeutics DWTX Sale Of Stock Consideration Received On Transaction
Sale Of Stock Consideration Received On Transaction at other companies
Other financials
Where this comes from
Reported directly by Dogwood Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:SaleOfStockConsiderationReceivedOnTransaction.
The official record: Dogwood Therapeutics’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →
Ask your AI about Dogwood Therapeutics's sale of stock consideration received on transaction.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Dogwood Therapeutics's sale of stock consideration received on transaction?
- Dogwood Therapeutics (DWTX) reported sale of stock consideration received on transaction of $11.4M in Q1 2026.
- How has Dogwood Therapeutics's sale of stock consideration received on transaction changed year-over-year?
- Dogwood Therapeutics's sale of stock consideration received on transaction increased by 160.7% year-over-year, from $4.37M to $11.4M.
- What does sale of stock consideration received on transaction mean?
- Captures the value of consideration received from the sale or disposal of equity interests in other entities or business units. This metric reflects the monetization of non-core assets or strategic divestitures. It provides insight into the company's ability to generate liquidity through portfolio optimization.